Opposite effects of transforming growth factor alpha and epidermal growth factor on mouse placental lactogen I secretion. 1995

M Yamaguchi, and L Ogren, and H Kurachi, and K Hirota, and T Imai, and F Talamantes
Department of Biology, University of California, Santa Cruz 95064, USA.

This study was undertaken to determine whether transforming growth factor alpha (TGF-alpha) regulates the production of mouse placental lactogen I (mPL-I) and mPL-II in a manner that is similar to that of epidermal growth factor (EGF), which was previously shown to stimulate mPL-I secretion and inhibit mPL-II secretion. In contrast to the activity of EGF, human (h) and rat (r) TGF-alpha (each at 100 ng/ml) inhibited secretion of mPL-I by placental cells isolated from mice on day 7 of pregnancy. Maximum inhibition of mPL-I secretion occurred on the third day of a 5-day culture period and ranged between 37% and 56% in multiple trials. Incubation of cells with hTGF-alpha and EGF was not followed by a change in the mPL-I concentration of the medium, suggesting the peptides antagonized each other's effects. hTGF-alpha and rTGF-alpha inhibited secretion of mPL-II; maximum inhibition ranged between 62% and 84% in multiple trials. The lowest concentrations of hTGF-alpha that affected mPL-I and mPL-II secretion were 10 ng/ml and 1 ng/ml, respectively. EGF and hTGF-alpha bound to the same receptors on placental cells, as assessed by cross-linking, and both peptides stimulated receptor phosphorylation, as assessed by Western blot analysis. There are three types of mPL-containing cells in placental cultures: cells that contain only mPL-I, cells that contain only mPL-II, and cells that contain both mPLs. The percentage of each type of mPL-containing cell in the culture was determined by immunostaining. hTGF-alpha affected the differentiation of the subpopulations of PL-containing cells in a manner that differed from that of EGF. The data suggest that TGF-alpha and EGF do not regulate the production of mPL-I and mPL-II in a similar manner.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007700 Kinetics The rate dynamics in chemical or physical systems.
D010920 Placenta A highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products. It includes a fetal portion (CHORIONIC VILLI) derived from TROPHOBLASTS and a maternal portion (DECIDUA) derived from the uterine ENDOMETRIUM. The placenta produces an array of steroid, protein and peptide hormones (PLACENTAL HORMONES). Placentoma, Normal,Placentome,Placentas,Placentomes
D010928 Placental Lactogen A polypeptide hormone of approximately 25 kDa that is produced by the SYNCYTIOTROPHOBLASTS of the PLACENTA, also known as chorionic somatomammotropin. It has both GROWTH HORMONE and PROLACTIN activities on growth, lactation, and luteal steroid production. In women, placental lactogen secretion begins soon after implantation and increases to 1 g or more a day in late pregnancy. Placental lactogen is also an insulin antagonist. Choriomammotropin,Chorionic Somatomammotropin, Human,Human Placental Lactogen,Lactogen Hormone, Placental,Mammotropic Hormone, Placental,Somatomammotropin, Chorionic,Choriomammotrophin,HCS (Human Chorionic Somatomammotropin),HPL (Human Placental Lactogen),PAPP-D,Placental Luteotropin,Pregnancy-Associated Plasma Protein D,Chorionic Somatomammotropin,Human Chorionic Somatomammotropin,Lactogen, Placental,Luteotropin, Placental,Placental Lactogen, Human,Placental Mammotropic Hormone,Pregnancy Associated Plasma Protein D
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004815 Epidermal Growth Factor A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form. EGF,Epidermal Growth Factor-Urogastrone,Urogastrone,Human Urinary Gastric Inhibitor,beta-Urogastrone,Growth Factor, Epidermal,Growth Factor-Urogastrone, Epidermal,beta Urogastrone
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Yamaguchi, and L Ogren, and H Kurachi, and K Hirota, and T Imai, and F Talamantes
October 1996, Journal of endocrinological investigation,
M Yamaguchi, and L Ogren, and H Kurachi, and K Hirota, and T Imai, and F Talamantes
August 1995, Biology of reproduction,
M Yamaguchi, and L Ogren, and H Kurachi, and K Hirota, and T Imai, and F Talamantes
June 1998, Endocrine journal,
M Yamaguchi, and L Ogren, and H Kurachi, and K Hirota, and T Imai, and F Talamantes
March 1996, Journal of endocrinological investigation,
M Yamaguchi, and L Ogren, and H Kurachi, and K Hirota, and T Imai, and F Talamantes
December 1995, European journal of endocrinology,
M Yamaguchi, and L Ogren, and H Kurachi, and K Hirota, and T Imai, and F Talamantes
July 1991, Endocrinology,
M Yamaguchi, and L Ogren, and H Kurachi, and K Hirota, and T Imai, and F Talamantes
April 1989, British medical bulletin,
M Yamaguchi, and L Ogren, and H Kurachi, and K Hirota, and T Imai, and F Talamantes
December 1991, Bailliere's clinical endocrinology and metabolism,
M Yamaguchi, and L Ogren, and H Kurachi, and K Hirota, and T Imai, and F Talamantes
November 1991, Endocrinology,
M Yamaguchi, and L Ogren, and H Kurachi, and K Hirota, and T Imai, and F Talamantes
May 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research,
Copied contents to your clipboard!